2026 China NRDL Changes
Verified comparison of the 2026 NRDL against the 2025 baseline edition (医保发〔2025〕33号). Launch sample includes 15 manually audited changes across additions, all 4 non-renewed transition removals, and major payment scope expansions.
2026 catalogs published Nov 14, 2026·Effective Jan 1, 2027— 4 non-renewed negotiated drugs retain transition coverage through Jun 30, 2027
| Drug | Change Type & Summary | Status | Effective / Transition | Source |
|---|---|---|---|---|
| Mazdutide 玛仕度肽 Not in 2025 → 2026 #30 | Added Newly added to 2026 NRDL Negotiated List (#30, Class B, price redacted *); restricted to adults with Type 2 Diabetes mellitus (weight management indication not reimbursed). 新增纳入2026版谈判药品第30项(乙类,支付标准*),限成人2型糖尿病患者;协议期2027-01-01至2028-12-31。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.119 Verified 2026-11-20 |
| Relmacabtagene autoleucel 瑞基奥仑赛 Not in 2025 → 2026 #297 | Added Newly added to 2026 NRDL Negotiated List (#297, Class B, *) across 3 lymphoma indications (r/r LBCL, r/r FL, r/r MCL); transitioned out of the 2025 Commercial List (#12). 由2025版商保创新药目录(第12项)转入2026版基本医保谈判药品第297项(乙类,支付标准*),覆盖LBCL、FL及MCL三项适应症。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.149 Verified 2026-11-20 |
| Insulin icodec / Semaglutide 依柯胰岛素司美格鲁肽 Not in 2025 → 2026 #18 | Added Newly added to 2026 NRDL Negotiated List (#18, Class B, *) for adult T2D inadequately controlled on basal insulin or GLP-1 receptor agonist. 新增纳入2026版谈判药品第18项(乙类,支付标准*),限基础胰岛素或GLP-1受体激动剂控制不佳的成人2型糖尿病患者。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.118 Verified 2026-11-20 |
| Zolbetuximab 佐妥昔单抗 Not in 2025 → 2026 #287 | Added Newly added to 2026 NRDL Negotiated List (#287, Class B, *) for first-line CLDN18.2+ HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with chemo. 新增纳入2026版谈判药品第287项(乙类,支付标准*),限一线治疗CLDN18.2阳性、HER2阴性局部晚期或转移性胃/GEJ腺癌。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.148 Verified 2026-11-20 |
| Datopotamab deruxtecan 德达博妥单抗 Not in 2025 → 2026 #288 | Added Newly added to 2026 NRDL Negotiated List (#288, Class B, *) for adult HR+/HER2- unresectable or metastatic breast cancer after prior ET and ≥1L chemo. 新增纳入2026版谈判药品第288项(乙类,支付标准*),限既往接受过内分泌治疗且晚期经≥1线化疗的HR阳性HER2阴性乳腺癌。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.148 Verified 2026-11-20 |
| Sapropterin dihydrochloride 盐酸沙丙蝶呤 Not in 2025 → 2026 #42 | Added Newly added to 2026 NRDL Negotiated List (#42, Class B, ¥62.00 per 100mg tablet) for BH4-deficiency HPA; transitioned from the 2025 Commercial List (#2). 由2025版商保创新药目录(第2项)转入2026版基本医保谈判药品第42项(乙类,62.00元/100mg片),限BH4缺乏症所致HPA。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.120 Verified 2026-11-20 |
| Pamiparib 帕米帕利 2025 #256 → Removed | Removed Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #256); 6-month transition period under original payment standard runs through Jun 30, 2027. 未成功续约调出2026版目录(原2025版谈判第256项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 Transition to Jun 30, 2027 | NHSA · Section I(1) Transition Clause Verified 2026-11-20 |
| Beraprost sodium (sustained-release) 贝前列素钠缓释片 2025 #40 → Removed | Removed Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #40); 6-month transition period under original payment standard runs through Jun 30, 2027. 未成功续约调出2026版目录(原2025版谈判第40项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 Transition to Jun 30, 2027 | NHSA · Section I(1) Transition Clause Verified 2026-11-20 |
| Xiao'er Niuhuang Qingxin San 小儿牛黄清心散 2025 #20 → Removed | Removed Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated TCM #20); 6-month transition period under original payment standard runs through Jun 30, 2027. 未成功续约调出2026版目录(原2025版谈判中成药第20项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 Transition to Jun 30, 2027 | NHSA · Section I(1) Transition Clause Verified 2026-11-20 |
| Shenlong Ningxin Capsules 参龙宁心胶囊 2025 #26 → Removed | Removed Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated TCM #26); 6-month transition period under original payment standard runs through Jun 30, 2027. 未成功续约调出2026版目录(原2025版谈判中成药第26项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 Transition to Jun 30, 2027 | NHSA · Section I(1) Transition Clause Verified 2026-11-20 |
| Dupilumab 度普利尤单抗 2025 #93 → 2026 #104 | Payment Scope Changed Expanded from 1 indication (atopic dermatitis) in 2025 (#93) to 5 indications in 2026 (#104): added prurigo nodularis, asthma (≥6y), eosinophilic COPD, and bullous pemphigoid. 支付范围由2025版单一项(特应性皮炎)扩增至5项,新增结节性痒疹、6岁及以上哮喘、嗜酸性粒细胞升高COPD及大疱性类天疱疮。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.126 Verified 2026-11-20 |
| Trastuzumab deruxtecan 德曲妥珠单抗 2025 #228 → 2026 #255 | Payment Scope Changed Expanded from 2 breast cancer settings in 2025 (#228) to 7 indications in 2026 (#255), adding HR+ HER2-low/ultralow BC, neoadjuvant HER2+ BC, 2L/3L+ HER2+ gastric/GEJ, and HER2-mutant NSCLC. 支付范围由2025版2项扩增至7项,新增HR+ HER2低/超低表达乳腺癌、HER2+乳腺癌新辅助、HER2+胃/GEJ腺癌(二线及三线以上)及HER2突变NSCLC。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.142 Verified 2026-11-20 |
| Sacituzumab tirumotecan 芦康沙妥珠单抗 2025 #252 → 2026 #284 | Payment Scope Changed Expanded from 2 indications in 2025 (#252) to 4 indications in 2026 (#284), adding HR+/HER2- breast cancer (post-ET/chemo) and earlier post-EGFR-TKI non-squamous NSCLC. 支付范围由2025版2项扩增至4项,新增HR+/HER2-乳腺癌及经EGFR-TKI治疗进展后的EGFR突变非鳞状NSCLC(无需先经含铂化疗)。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.147 Verified 2026-11-20 |
| Ivosidenib 艾伏尼布 2025 #258 → 2026 #298 | Payment Scope Changed Expanded beyond r/r IDH1-mutated AML in 2025 (#258) to add first-line newly diagnosed IDH1-mutated AML combined with azacitidine (age ≥75 or intensive-chemo ineligible) in 2026 (#298). 支付范围新增联用阿扎胞苷一线治疗≥75岁或不耐受强诱导化疗的新诊断IDH1突变AML患者(原2025版仅限复发/难治AML)。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.149 Verified 2026-11-20 |
| Eliglustat tartrate 酒石酸艾格司他 2025 #38 → 2026 #41 | Payment Scope Changed Expanded from adult Gaucher disease type 1 in 2025 (#38, ¥381.00) to add pediatric GD1 patients (age ≥6y, weight ≥15kg, ERT-stable) in 2026 (#41, ¥361.95 per 84mg capsule). 支付范围新增6岁及以上且体重≥15公斤、ERT稳定的Ⅰ型戈谢病儿童患者,支付标准同步由381.00元调整为361.95元(84mg/粒)。 | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Announced Nov 14, 2026 | NHSA · PDF p.119 Verified 2026-11-20 |
| No. / Class | Drug & Listed Form | Payment Standard | 2026 Payment Scope | Agreement & Source |
|---|---|---|---|---|
| #18 · Class B | Insulin icodec / Semaglutide 依柯胰岛素司美格鲁肽注射液 (Injection) | * Confidential | Restricted to adults with Type 2 Diabetes mellitus inadequately controlled on basal insulin or a GLP-1 receptor agonist. 限接受基础胰岛素或胰高糖素样肽1(GLP-1)受体激动剂治疗后血糖控制不佳的成人2型糖尿病患者。 | 2027-01-01 → 2028-12-31 Announced · Effective Jan 1, 2027 |
| #30 · Class B | Mazdutide 玛仕度肽注射液 (Injection) | * Confidential | Restricted to adults with Type 2 Diabetes mellitus. 限成人2型糖尿病患者。 | 2027-01-01 → 2028-12-31 Announced · Effective Jan 1, 2027 |
| #41 · Class B | Eliglustat tartrate 酒石酸艾格司他胶囊 (Capsule) | 361.95元(84mg/粒(按C23H36N2O4计)) | Expanded to cover both adult GD1 patients and pediatric GD1 patients (age ≥6 years, weight ≥15 kg, stable on ERT) who are CYP2D6 PMs, IMs, or EMs; published standard adjusted from ¥381.00 to ¥361.95 per 84mg capsule. 限:1.经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)成年患者;2.6岁及以上,体重15公斤及以上,酶替代治疗(ERT)稳定,以及经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)儿童患者的治疗。 | 2027-01-01 → 2027-12-31 Announced · Effective Jan 1, 2027 |
| #42 · Class B | Sapropterin dihydrochloride 盐酸沙丙蝶呤片 (Tablet) | 62.00元(100mg/片) | Restricted to hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency. 限四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA)。 | 2027-01-01 → 2028-12-31 Announced · Effective Jan 1, 2027 |
| #104 · Class B | Dupilumab 度普利尤单抗注射液 (Injection) | * Confidential | Restricted to 5 indications: (1) Moderate-to-severe atopic dermatitis; (2) Adult moderate-to-severe prurigo nodularis; (3) Maintenance asthma in patients ≥6 years (type 2 inflammation with eosinophils ≥300/μL or OCS-dependent); (4) Uncontrolled eosinophilic COPD in adults (≥300/μL) on triple/dual therapy; (5) Adult bullous pemphigoid. 限:1.对传统治疗无效、有禁忌或不耐受的中重度特应性皮炎患者,需按说明书用药;2.治疗适合系统治疗的中度至重度结节性痒疹的成人患者;3.6岁及以上儿童和成人哮喘患者的维持治疗(伴有2型炎症嗜酸性粒细胞≥300个/μL或口服糖皮质激素依赖性);4.三联/二联治疗未控制的嗜酸性粒细胞升高(≥300个/μL)慢性阻塞性肺疾病(COPD)成人患者维持治疗;5.治疗大疱性类天疱疮的成人患者。 | 2027-01-01 → 2028-12-31 Announced · Effective Jan 1, 2027 |
| #255 · Class B | Trastuzumab deruxtecan 注射用德曲妥珠单抗 (Powder for Injection) | * Confidential | Expanded to 7 indications: (1) ≥2L HER2+ mBC; (2) HER2-low mBC; (3) HR+ HER2-low/ultralow mBC post-ET; (4) Neoadjuvant HER2+ stage II high-risk/III BC seq. THP; (5) ≥3L HER2+ gastric/GEJ; (6) ≥2L HER2+ gastric/GEJ post-trastuzumab; (7) ≥2L HER2 (ERBB2)-mutant NSCLC. 限:1.HER2阳性不可切除/转移性乳腺癌(≥1线抗HER2后);2.HER2低表达不可切除/转移性乳腺癌(化疗后);3.HR阳性HER2低表达或HER2超低表达(IHC 0伴细胞膜染色)乳腺癌(内分泌治疗进展后单药);4.序贯THP用于HER2阳性Ⅱ期(高危)或Ⅲ期乳腺癌新辅助治疗;5.HER2阳性局部晚期/转移性胃或GEJ腺癌(≥2线后);6.HER2阳性局部晚期/转移性胃或GEJ腺癌(≥1线含曲妥珠单抗方案后);7.HER2(ERBB2)激活突变不可切除/转移性NSCLC(≥1线系统治疗后)。 | 2027-01-01 → 2028-12-31 Announced · Effective Jan 1, 2027 |
| #284 · Class B | Sacituzumab tirumotecan 注射用芦康沙妥珠单抗 (Powder for Injection) | * Confidential | Expanded to 4 indications: (1) ≥3L TNBC; (2) HR+/HER2- unresectable/metastatic BC post-ET and ≥1L chemo; (3) EGFR-mutated non-squamous NSCLC post-EGFR-TKI and platinum chemo; (4) Earlier-line EGFR-mutated non-squamous NSCLC post-EGFR-TKI alone. 限:1.既往至少接受过2种系统治疗的不可切除局部晚期或转移性三阴性乳腺癌成人患者;2.既往接受过内分泌治疗且在晚期阶段接受过至少一线化疗的不可切除或转移性HR阳性HER2阴性(IHC 0、1+或2+/ISH-)乳腺癌成人患者;3.经EGFR-TKI和含铂化疗进展的EGFR突变阳性非鳞状NSCLC;4.经EGFR-TKI治疗后进展的EGFR突变阳性非鳞状NSCLC成人患者。 | 2027-01-01 → 2027-12-31 Announced · Effective Jan 1, 2027 |
| #287 · Class B | Zolbetuximab 注射用佐妥昔单抗 (Powder for Injection) | * Confidential | Restricted to first-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-based chemotherapy. 限联合含氟尿嘧啶类和铂类药物化疗用于CLDN18.2阳性、人表皮生长因子受体2(HER2)阴性的局部晚期不可切除或转移性胃或胃食管交界处(GEJ)腺癌患者的一线治疗。 | 2027-01-01 → 2028-12-31 Announced · Effective Jan 1, 2027 |
| #288 · Class B | Datopotamab deruxtecan 注射用德达博妥单抗 (Powder for Injection) | * Confidential | Restricted to adults with unresectable or metastatic HR-positive, HER2-negative (IHC 0, 1+, or 2+/ISH-) breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced setting. 限既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、人类表皮生长因子受体2(HER2)阴性(IHC 0、IHC 1+或IHC 2+/ISH-)乳腺癌成人患者。 | 2027-01-01 → 2028-12-31 Announced · Effective Jan 1, 2027 |
| #297 · Class B | Relmacabtagene autoleucel 瑞基奥仑赛注射液 (Injection (CAR-T)) | * Confidential | Restricted to: (1) Adult r/r LBCL (DLBCL NOS, PMBCL, HGBL double/triple-hit) after ≥2 prior systemic therapies; (2) Adult refractory or ≤24-month relapsed grade 1–3a follicular lymphoma after ≥2 prior lines; (3) Adult r/r mantle cell lymphoma after ≥2 prior lines including a BTK inhibitor. 限:1.经过二线或以上系统性治疗后成人患者的复发或难治性大B细胞淋巴瘤,包括弥漫性大B细胞淋巴瘤非特指型、原发纵隔大B细胞淋巴瘤、高级别B细胞淋巴瘤伴MYC和BCL-2和/或BCL-6重排(双打击/三打击淋巴瘤);2.经过二线或以上系统性治疗的成人难治性或24个月内复发的滤泡性淋巴瘤,包括组织学分级为1、2、3a级的滤泡性淋巴瘤;3.经过包括布鲁顿酪氨酸激酶抑制剂(BTKi)治疗在内的二线及以上系统性治疗的成人复发或难治性套细胞淋巴瘤。 | 2027-01-01 → 2028-12-31 Announced · Effective Jan 1, 2027 |
| #298 · Class B | Ivosidenib 艾伏尼布片 (Tablet) | * Confidential | Expanded to 2 indications: (1) Adult r/r IDH1-mutated AML; (2) First-line newly diagnosed IDH1-mutated AML in combination with azacitidine for patients aged ≥75 or ineligible for intensive induction chemotherapy. 限:1.携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者;2.联合阿扎胞苷用于携带易感异柠檬酸脱氢酶-1(IDH1)突变,因合并症无法使用强诱导化疗或者年龄≥75岁的新诊断急性髓系白血病(AML)患者。 | 2027-01-01 → 2027-12-31 Announced · Effective Jan 1, 2027 |
| No. / Class | Drug & Listed Form | 2025 Payment Standard | 2025 Payment Scope | Agreement & Source |
|---|---|---|---|---|
| #20 · Class B tcm | Xiao'er Niuhuang Qingxin San 小儿牛黄清心散 (Oral Powder (TCM)) | 2.36元(0.3g/袋);4.01元(0.6g/袋) | Restricted to emergency/resuscitation use for high fever with altered consciousness. 限高热神昏的急救、抢救时使用。 | 2025-01-01 → 2026-12-31 Removed in 2026 · Transition to 2027-06-30 |
| #26 · Class B tcm | Shenlong Ningxin Capsules 参龙宁心胶囊 (Capsule (TCM)) | 0.35元(0.5g/粒) | Restricted to mild-to-moderate premature ventricular contractions associated with coronary heart disease or convalescent adult viral myocarditis matching listed TCM syndrome. 限冠心病和成年人恢复期病毒型心肌炎出现的轻度或中度室性过早搏动见上述证候者。 | 2025-01-01 → 2026-12-31 Removed in 2026 · Transition to 2027-06-30 |
| #38 · Class B negotiated | Eliglustat tartrate 酒石酸艾格司他胶囊 (Capsule) | 381.00元(84mg/粒(按C23H36N2O4计)) | Restricted to adult Gaucher disease type 1 (GD1) patients who are CYP2D6 poor, intermediate, or extensive metabolizers. 限经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)成年患者。 | 2026-01-01 → 2027-12-31 |
| #40 · Class B negotiated | Beraprost sodium (sustained-release) 贝前列素钠缓释片 (Sustained-Release Tablet) | * Confidential | Restricted to WHO Group 1 pulmonary arterial hypertension (PAH), WHO Functional Class I–III, to improve exercise capacity. 限WHO功能分级Ⅰ级-Ⅲ级的肺动脉高压(PAH,WHO第1组)的患者,以改善患者的运动能力。 | 2025-01-01 → 2026-12-31 Removed in 2026 · Transition to 2027-06-30 |
| #93 · Class B negotiated | Dupilumab 度普利尤单抗注射液 (Injection) | * Confidential | Restricted to moderate-to-severe atopic dermatitis refractory, contraindicated, or intolerant to conventional therapy, per approved label. 限对传统治疗无效、有禁忌或不耐受的中重度特应性皮炎患者,需按说明书用药。 | 2025-01-01 → 2026-12-31 |
| #228 · Class B negotiated | Trastuzumab deruxtecan 注射用德曲妥珠单抗 (Powder for Injection) | * Confidential | Restricted to 2 breast cancer settings: (1) Unresectable/metastatic HER2+ breast cancer after ≥1 prior anti-HER2 therapy; (2) Unresectable/metastatic HER2-low (IHC 1+ or 2+/ISH-) breast cancer after prior systemic therapy or ≤6-month adjuvant recurrence. 限:1.既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者;2.既往在转移性疾病阶段接受过至少一种系统治疗的,或在辅助化疗期间或完成辅助化疗之后6个月内复发的,不可切除或转移性HER2低表达(IHC 1+或IHC 2+/ISH-)成人乳腺癌患者。 | 2025-01-01 → 2026-12-31 |
| #252 · Class B negotiated | Sacituzumab tirumotecan 注射用芦康沙妥珠单抗 (Powder for Injection) | * Confidential | Restricted to 2 indications: (1) ≥3L unresectable/metastatic TNBC; (2) EGFR-mutated locally advanced/metastatic non-squamous NSCLC after both EGFR-TKI and platinum-based chemotherapy. 限:1.既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌成人患者;2.经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)和含铂化疗治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)成人患者。 | 2026-01-01 → 2027-12-31 |
| #256 · Class B negotiated | Pamiparib 帕米帕利胶囊 (Capsule) | * Confidential | Restricted to patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after ≥2 prior lines of chemotherapy. 限既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者。 | 2026-01-01 → 2027-12-31 Removed in 2026 · Transition to 2027-06-30 |
| #258 · Class B negotiated | Ivosidenib 艾伏尼布片 (Tablet) | * Confidential | Restricted to adults with relapsed or refractory AML with a susceptible IDH1 mutation. 限诊断为携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者。 | 2026-01-01 → 2027-12-31 |